Overview

Study Using CABENUVA™ for the Treatment of Human Immunodeficiency Virus (HIV)-1, Administered in Infusion Centers (IC) in the United States (U.S.)

Status:
Not yet recruiting
Trial end date:
2023-02-17
Target enrollment:
Participant gender:
Summary
GLACIER (Giving Long Acting CABENUVA in an Infusion centER) is an interventional study examining the administration of CABENUVA (Cabotegravir long acting [LA] plus Rilpivirine LA) intramuscular (IM) in infusion centers in South-eastern United States. In this study, the intervention is the process of using an infusion center as the location to receive the CABENUVA IM injections. The acceptability and feasibility of the IC to deliver CABENUVA IM injections will be assessed from the perspectives of the participants, HIV care providers and IC staff. In this study, Month 1 is the Baseline visit. CABENUVA is a registered trademark of ViiV Healthcare.
Phase:
Phase 4
Details
Lead Sponsor:
ViiV Healthcare